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Abstract
Background: Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and
mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-
treatment duration with a possibility of non-adherence, drug interactions, and toxicities. Dose escalation of
rifampicin, an important drug within the regimen, has been proposed as a potential route to higher
treatment efficacy with shorter duration and some studies have suggested that dose escalation is safe;
however, these have almost entirely been conducted among human immunodeficiency (HIV)-negative TB
patients. TB-HIV co-infected patients on antiretroviral therapy (ART) are at increased risk of drug-drug
interactions and drug-related toxicities. This study aims to determine the safety of higher doses of
rifampicin and its effect on the pharmacokinetics of efavirenz (EFV) and dolutegravir (DTG) in TB-HIV co-
infected patients.
Methods: This study is a randomized, open-label, phase IIb clinical trial among TB-HIV infected adult
outpatients attending an HIV clinic in Kampala, Uganda. Patients newly diagnosed with TB will be
randomized to either standard-dose or high-dose rifampicin (35 mg/kg) alongside standard TB treatment.
ART-naïve patients will be randomly assigned to first-line ART regimens (DTG or EFV). Those who are
already on ART (DTG or EFV) at enrollment will be continued on the same ART regimen but with dose
adjustment of DTG to twice daily dosing. Participants will be followed every 2 weeks with assessment for
toxicities at each visit and measurement of drug concentrations at week 6. At the end of intensive-phase
therapy (8 weeks), all participants will be initiated on continuation-phase treatment using standard-dose
rifampicin and isoniazid.
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Discussion: This study should avail us with evidence about the effect of higher doses of rifampicin on the
pharmacokinetics of EFV and DTG among TB-HIV co-infected patients. The trial should also help us to
understand safety concerns of high-dose rifampicin among this vulnerable cohort.
Trial registration: ClinicalTrials.gov, ID: NCT03982277. Registered retrospectively on 11 June 2019.
Keywords: Rifamycins, Antiretrovirals, HIV, Pharmacokinetics, Tuberculosis,
Background
Tuberculosis (TB) is a significant public health bur-
den that causes substantial morbidity and mortality.
Globally, approximately 10 million people developed
TB in 2017, 9% of whom were people living with hu-
man immunodeficiency (HIV) (72% of these residing
in Africa). Eighty-seven percent of all the world’s TB
cases were accounted for by the 30 high-burden TB
countries [1].
Rifampicin is a key component of current first-line
TB treatment. It contributes to rapid bactericidal ac-
tivity during the first few days of TB treatment, and
it has a sterilizing effect that lasts throughout the
treatment course [2]. Even with good adherence to
therapy inter-individual plasma exposure to rifampi-
cin is known to be variable. Low exposure has been
associated with drug resistance, treatment failure,
and delayed bacterial clearance from sputum [3–5].
Higher doses of rifampicin have been associated with
a faster drop in bacterial load over time. Shorter
treatment regimens including high-dose rifampicin
are currently being investigated [6]. Several studies
have suggested that dose escalation is safe; however,
these have almost entirely been conducted among
HIV-negative TB patients, or TB-HIV co-infected pa-
tients without severe immunosuppression who were
not yet receiving antiretroviral therapy (ART) [7, 8].
TB-HIV co-infected patients on multiple additional
drugs, including ART, are at increased risk of drug-
drug interactions and drug-related toxicities, includ-
ing hepatotoxicity [9, 10].
Rifampicin induces a plethora of metabolic processes
through the pregnane-x receptor [11], including cyto-
chrome P450A, thus leading to several drug-drug inter-
actions. While a few small studies suggest that maximal
induction already occurs at relatively low doses of rifam-
picin, the dose that achieves the maximal induction ef-
fect is still unknown.
Rifampicin induces CYP2B6 (responsible for efavir-
enz (EFV) metabolism) and UGT1A1, and CYP3A4
(responsible for dolutegravir (DTG) metabolism).
Although earlier studies demonstrated that the
standard-dose rifampicin does not significantly
decrease EFV concentrations, (which in some studies
has been attributed to the inhibitory effect of
isoniazid on cytochrome P450 2A6 [12, 13]), and
doubling the dose of DTG overcomes the enzyme-
induction effect, the consequences of administering
higher doses of rifampicin for HIV-TB co-infected
patients on ART requires specific, careful evaluation
[14, 15].
Rifampicin-dose escalation may help to improve
TB treatment outcomes. However, there is almost no
information on the enzyme-induction effect of high-
dose rifampicin on EFV and DTG and a paucity of
data on the safety of higher rifampicin doses in
HIV-infected patients on ART. If higher doses of ri-
fampicin are to be considered for routine TB treat-
ment in African countries, such data will be critical
for the high number of HIV co-infected persons.
The aim of this study is to determine the effect of
higher-dose rifampicin on the pharmacokinetics (PK)
of EFV and DTG in TB-HIV co-infected patients,
and to establish whether higher-dose rifampicin is
safe for HIV-infected patients with TB.
Methods
Study site
This study is being conducted at the integrated TB-HIV
Outpatient Clinic of the Infectious Diseases Institute
Makerere University College of Health Sciences in
Kampala, Uganda, which is an urban outpatient HIV
clinic that provides care to 200 patients infected with TB
annually.
Study design
This is a randomized, open-label, phase IIb clinical trial
of HIV-infected patients newly diagnosed with TB.
Study population
Patients are enrolled if they fulfill the following in-
clusion criteria: (1) adults of age ≥ 18 years, (2) con-
firmed HIV-1 infection, (3) already started on EFV-
or DTG-based ART or planned to start on ART
(national first-line regimens are DTG- or EFV-
based), and (4) diagnosed with TB and due to initi-
ate rifampicin-containing therapy.
Patients will be excluded if they meet any one of
the following criteria: (1) have rifampicin-resistant
TB identified by baseline Xpert Mycobacterium
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tuberculosis/rifampicin (MTB/RIF), (2) pregnant
women, (3) women of reproductive age on DTG who
decline the use of effective contraception methods
(in particular: intrauterine device or condoms and
dual contraception for those on hormonal methods),
(4) decompensated liver disease and/or aminotrans-
ferases > 5 x upper limit of normal (ULN), and (5)
glomerular filtration rate (GFR) < 50 ml/min.
Study objectives
Primary objective
1. To determine the effect of a high dose of rifampicin
(35 mg/kg orally) on the PK of first-line antiretro-
viral drugs (EFV and DTG) in TB-HIV co-infected
patients on TB treatment
Secondary objectives
2. To investigate the safety/tolerability of higher doses
of rifampicin in TB-HIV co-infected patients on TB
treatment and first-line antiretroviral drugs (EFV
and DTG)
3. To determine if TB-HIV co-infected patients on
higher doses of rifampicin are more likely to have
negative sputum cultures by the end of the intensive
phase of TB treatment than patients on standard-
dose rifampicin
4. To explore the relationships between exposure to
rifampicin, EFV, and DTG and the tolerability and
efficacy of these drugs (PK-pharmacodynamic (PD)
analysis)
Study hypotheses
 Patients on a high dose of rifampicin will have a
minimal decrease in exposure to EFV and DTG
compared to those on standard-dose rifampicin
 A higher proportion of patients on first-line ART and
high-dose rifampicin will experience hepatotoxicity
compared to those on standard-dose rifampicin, but
this increase will be modest, and hepatotoxicity
events will be mostly low-grade
 A higher proportion of patients on high-dose rifampi-
cin will have negative cultures at week 8 compared to
those on standard-dose rifampicin
 Antiretroviral response will be similar among
patients who use standard- or high-dose rifampicin
as part of their TB treatment
TB diagnosis
TB is diagnosed using chest x-ray, sputum florescent mi-
croscopy or Xpert MTB/RIF, and a clinical history that
includes any one of the following symptoms: cough,
fever, weight loss, and drenching night sweats. Patients
with confirmed TB (positive Xpert, positive urinary
lipoarabinomannan (LAM), or TB adenitis confirmed by
Ziehl-Neelsen (ZN) staining or histopathology) are in-
cluded in the study.
Intervention
Participants are randomized to either standard-dose (10
mg/kg) or high-dose (35 mg/kg) rifampicin. All other
anti-TB drugs (isoniazid, ethambutol, and pyrazinamide
(HEZ)) are given at their standard dose for weight bands
using Fixed Dose Combination (FDC) tablets supplied
by the National TB Control Program. The patients on
high-dose rifampicin have their additional doses supple-
mented by rifampicin capsules.
ART-naïve patients are randomly assigned to first-
line ART regimens (DTG 50 mg twice daily or EFV
600 mg once daily) which is initiated 2 weeks into
TB treatment. Those who are already on ART at en-
rollment continue the same ART regimen; however,
participants on DTG are switched to twice-daily
DTG while they are on rifampicin. EFV/DTG is
given in combination with tenofovir, zidovudine, or
abacavir plus either lamivudine or emtricitabine.
Most patients are given tenofovir/lamivudine as
backbone therapy because it is the preferred first-
line backbone therapy nationally and they are only
offered zidovudine or abacavir if there are contrain-
dications to tenofovir. Viral-load measurements are
performed at baseline (for patients on ART at base-
line) and at the week-24 visit (6 months after initi-
ation of ART).
Participants are followed up every 2 weeks for
study procedures including assessment for toxicities
(Figs. 2 and 3 in Appendix). At the end of the inten-
sive phase (8 weeks), all participants will be initiated
on the continuation phase using standard-dose ri-
fampicin and isoniazid. Adherence is monitored
using pill counts and self-report.
Randomization process
Randomization is done by the trial pharmacist using
a computer-generated randomization code that as-
signs participants to four treatment allocation groups
(refer to Fig. 1 below), with 30 participants in each
group: (1) high-dose rifampicin and DTG, (2)
standard-dose rifampicin and DTG,.(3) high-dose ri-
fampicin and EFV, and (4) standard-dose rifampicin
and EFV. Details of a patient’s allocation is then no-
tified to the study coordinator immediately. This is
an open-label study; however, participants and data
analysts are blinded to the treatment arm through
the use of anonymized codes during sample collec-
tion and analysis.
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Pharmacokinetic measurements
Blood sampling for PK analysis is performed 6 weeks
after initiation of TB treatment. On the study visit,
participants come to the clinic in the morning after
fasting overnight and observed intake of anti-TB
drugs and the morning dose of DTG occurs. Blood
samples to measure rifampicin and dolutegravir con-
centrations are drawn prior to drug intake (0 h), and
at 1, 2, 4, and 8 h following observed intake of the
anti-TB drugs. Mid-dose EFV concentrations are
measured at 0 h.
The blood samples are immediately placed in a
dark cooler and transported to the laboratory within
30 min of collection, after which samples are centri-
fuged, aliquoted, batched, and frozen at − 80 °C until
quantification of drug concentrations is done. Quan-
tification of the drug concentrations (rifampicin,
EFV, DTG) will be performed using pre-established,
validated, high-performance liquid chromatography
(HPLC) assays.
Microbiological assessment
Sputum samples are collected from patients with
pulmonary TB for culture on liquid medium (Myco-
bacteria Growth Indicator Tube (MGIT) and solid
medium (BACTEC) at baseline and 8 weeks of anti-
TB treatment. Additional samples will be collected
for storage every 2 weeks during the first 2 months
of TB treatment, for storage for future cultures using
mycobacterial-load assay.
Adverse event assessment
Participants are assessed for adverse events on every
study visit using direct questioning, physical examin-
ation, and laboratory parameters; alanine transferase
(ALT) and bilirubin (2 weekly) and creatinine (4
weekly). The severity of liver toxicity is graded ac-
cording to the National Institutes of Health DAIDS
[14]. Study medication will be stopped when either
of the following occurs: (1) symptoms of hepatitis
(for example, abdominal pain, nausea, vomiting, mal-
aise) and ALT measurement ≥ 3 times the ULN, (2)
ALT is ≥ 5 times the ULN regardless of symptoms,
and (3) any toxicity that, in the investigator’s judg-
ment, is due to study drug and requires interruption
of treatment with the causative study drug. Causality
assessment for all adverse events will be performed
and classified as either definite, probable, possible,
unlikely or unrelated. serious adverse events will be
reported to the sponsor within 24 h and the regula-
tory authorities within 7 days.
Anti-TB medication, under the standard of care, will
be reintroduced at their standard doses when ALT is
within the normal range. All serious adverse events are
followed up until resolution even after participants are
withdrawn from study.
Fig. 1 Diagram showing the randomization process
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There is no anticipated harm and compensation for
trial participation.
Additional blood samples will be stored at baseline,
weeks 2, 4, 6, and 8 for validation of new biomarkers
used for early detection of drug-induced liver injury.
Data analysis
Sample size calculation
We applied a sample size calculation using coeffi-
cient of variation and percentage change in geomet-
ric mean of EFV mid-dose concentrations. This
study is powered on the primary endpoint of mid-
dose EFV concentrations. We varied the difference
in the concentrations among the different dose arms
(high-dose arm vs. standard-dose arm) between 5
and 30%, which is close to the bioequivalence ac-
cepted by the Food and Drug Authority. With a
power of 80%, a difference in mid-dose EFV concen-
trations of 30% and assuming loss to follow-up of
25%, we would need a sample size of 120 partici-
pants (30 patients in each group). Patients are ac-
tively referred from city council hospitals in order to
achieve our sample size within the target recruitment
period of 1 year.
Patient retention: the study team is responsible for
tracking participants using phone calls, and where
possible, home visits, to ensure retention rate. Loca-
tor information is collected and updated at each visit
where necessary. Outcome data will be collected
from patients who deviate or discontinue assigned
treatment on their clinic visits or through phone
interviews.
Analysis of endpoints
Primary objective (drug interactions)
We will compare the EFV mid-dose concentrations
and the trough concentrations of DTG in patients
on 35 mg/kg and 10 mg/kg doses using an independ-
ent samples T test on logarithmically transformed
PK measurements or a Wilcoxon rank sum test on
untransformed data.
Pharmacokinetic data
In addition, we will apply a population PK-modeling
approach for PK data. We will develop population
models to describe the PK parameters of rifampicin,
EFV, and DTG and the between-subject and
between-occasion variability in these parameters. The
models will be based on previously developed PK
models that will be adapted by fitting them to the
data collected in the study.
We will compare the proportions of patients who de-
velop liver toxicity and the severity/grade of liver toxicity
among patients on the different doses of rifampicin
using the chi-squared test. We will determine the associ-
ation between each rifampicin dose and hepatotoxicity
using Cox regression.
We will estimate the proportion of patients who
remain culture-positive after 8 weeks of anti-TB
treatment in each treatment arm and compare them
using the chi square test. Using non-linear mixed ef-
fects modeling, we will develop PK-PD models to de-
termine the relationship between PK exposure and
PD response including virological suppression, toxic-
ities, and bacteriological response.
Analysis of primary endpoint will be performed per
protocol whereas intention-to-treat analysis will be per-
formed as sensitivity analysis. Missing data on drug con-
centration will be imputed using multiple imputation
when performing sensitivity analysis.
Quality control and assurance
During the study, periodic monitoring is conducted to
ensure that the protocol and International Conference
on Harmonization-Good Clinical Practice (ICH-GCP)
principles are being followed. Additionally, the study site
may be subject to review by the Institutional Review
Board and the regulatory authorities.
Data handling and record retention
De-linked clinical and demographic data is collected
on Case Report Forms (CRF) and kept in a locked
cabinet with access granted only to authorized study
staff. Data from the CRFs is stored via Datafax,
which reads the data using intelligent character rec-
ognition and enters the data into a secure server at
the Infectious Diseases Institute. Data will be se-
curely stored for a minimum of 20 years according
to the local National Drug Authority regulations for
clinical trials.
The independent Data Safety and Monitoring
Board (DSMB) will make recommendations concern-
ing the study to the Trial Steering Committee. The
DSMB is chaired by Dr. Catriona Waitt a clinical
pharmacologist from the University of Liverpool and
based at the Infectious Diseases Institute, Kampala,
with experience in dose-finding PK studies, Dr. Ag-
nes Kiragga, a senior statistician at the Infectious
Diseases Institute with experience in HIV clinical tri-
als and cohort studies, Dr. Marta Boffito, the clinical
research lead at St Stephen’s AIDS Trust in the U.K,
who has extensive expertise in complex pharmaco-
logical issues, and Dr. Eric Decloedt, a registrar in
clinical pharmacology and a senior lecturer and re-
searcher at Stellenbosch University in South Africa.
The DSMB is independent from the sponsor and
has no competing interests. The first interim ana-
lysis will be conducted when 10% of the participants
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complete the study medication. Trial monitoring is
conducted independent of the investigators by in-
ternal monitors at the Infectious Diseases Institute.
The Trial Steering Committee is composed of
Dr. Stella Zawedde (chair), a representative from the
National Tuberculosis and Leprosy Program in
Uganda, Dr. Pauline Byakika-Kibwika and Associate
Professor David Meya, both infectious disease
specialists at the Department of Internal Medicine
of Makerere University, Dr. Susan Adakun, head of
the Mulago National Referral Hospital Tuberculosis
Unit, and Elizabeth Tindyebwa, a lay representative
from the Friends’ Council (patient group at IDI). Regular
discussions are held over email or conference calls when
required but at least once a year. The Trial Management
Group meets weekly and is responsible for the day-to-day
study activities. It is composed of the Dr. Christine
Sekaggya (principal investigator who provides overall
oversight), Dr. Derek Sloan, and Dr. Mohammed Lamorde
(co-investigators), Dr. Ruth Nabisere (trial manager),
Dr. Brian Otalo (study physician), Florence Aber, Juliet
Nampala (study nurses), Joseph Musaazi (statistician),
and Hamza Mayanja (pharmacist and person responsible
for randomization).
Ethical issues
All precautions are being made to ensure the safety
of patient data and identifying information. All pa-
tients provide written informed consent for partici-
pation in the study and the storage of biological
samples including blood, urine, and sputum for an-
cillary studies, a process conducted by the study
nurse and study coordinator.
Ethical approval for this study was sought from the
Joint Clinical Research Council (JC2218), the National
Drug Authority, and the Uganda National Council for
Science and Technology.
The study is being conducted in accordance with the
general principles set forth in the International Ethical
Guidelines for Biomedical Research Involving Human
Subjects and the Declaration of Helsinki and Good
Clinical Practice guidelines. The study is registered at
ClinicalTrials.gov, ID: NCT03982277. and has been re-
ported according to SPIRIT guidelines.
All protocol amendments will be first submitted to the
responsible regulatory bodies before implementation.
Protocol deviations will be reported to the regulatory
bodies within 7 days of site notification and recorded in
a protocol deviation log kept in the regulatory binder.
The protocol will also be updated at ClinicalTrials.gov.
Dissemination of results
Study results will be published in peer-reviewed journals
with open access. We will also present our findings to
the National TB Program, local, regional, and inter-
national conferences.
Discussion
This study is one of the few trials to investigate ri-
fampicin at 35 mg/kg, and the first ever to do so in
a higher-risk population (HIV-infected patients). It
should provide crucial evidence about the PK and
the safety of co-administration of EFV and DTG
with 35 mg/kg of rifampicin in a TB-HIV co-infected
population. We are including a population of pa-
tients with severe immunosuppression that will be
representative of the high proportion of TB patients,
who are also co-infected with HIV.
This study should be able to demonstrate whether
higher doses of rifampicin can be safely used in
HIV-positive patients on ART, and whether this has
an impact of their treatment outcomes with faster
mycobacterial-load clearance.
With the stored samples from this population, we
will conduct a pharmacogenomic analysis to under-
stand the role of genetic polymorphisms in the PK
of the investigated drugs and evaluate new molecular
assays that can be used for early detection of
hepatotoxicity.
However, the investigators also acknowledge some of
the anticipated challenges and/or limitations of this
study which include:
 There is need for more vigilant safety monitoring
coupled with a very strong Data and Safety
Monitoring Board due to the anticipated toxicities
and drug-drug interactions that we might experience
in the trial
 Secondly, there is no blinding in this clinical
trial, hence it is hard to completely rule out the
effect of bias in interpreting possible toxicities
that are not backed by objective laboratory
parameters
 Currently, because of the test-and-treat recommen-
dation, some patients are already on ART and,
therefore, randomization to ART for some patients
is not possible
Despite these, we believe that this study will demon-
strate that early phase trials can be successfully con-
ducted in resource-constrained settings where the
highest burden of the dual epidemic lies.
Trial status
The study, with protocol version 3, 17 December 2018,
began enrollment on 30 April 2019 and had recruited 37
participants by 18 October 2019. The expected end of
enrollment is 30 December 2020.
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Appendix
Fig. 2 Schedule of enrollment, interventions, and assessments
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